Pharmaceutical News

  • Novartis exits Bangladesh

    Switzerland-based Novartis AG has sold its 60% stake in Novartis Bangladesh Limited to Radiant Pharmaceuticals, marking its exit from Bangladesh’s pharmaceutical market. This departure follows similar exits by other multinational companies. Radiant will uphold Novartis’ legacy as it joins the top ten pharmaceutical firms in Bangladesh. Read more

  • Tonix Pharmaceuticals Reveals Promising TONMYA Phase 3 Trial Data

    Tonix Pharmaceuticals presented significant Phase 3 trial data for TONMYA™ at the 2026 Non-Opioid Pain Therapeutics Summit. The study indicated effective pain relief in fibromyalgia patients compared to placebo, with improvements in sleep and fatigue. Approved by the FDA in 2025, TONMYA is a non-opioid treatment option for this chronic condition. Read more

  • FDA Launches PreCheck Pilot to Boost US Pharmaceutical Manufacturing

    The FDA has launched the PreCheck pilot program to enhance domestic pharmaceutical manufacturing by streamlining regulations and facilitating new drug production facilities. The initiative, informed by industry feedback, aims to improve the U.S. pharmaceutical supply chain, prioritize critical medication production, and reduce reliance on overseas manufacturers, beginning in 2026. Read more

  • Eli Lilly to Invest $3.5 Billion in Pennsylvania Injectable Manufacturing Facility

    Eli Lilly plans to invest over $3.5 billion in a new manufacturing facility in Lehigh Valley, Pennsylvania, to produce innovative weight-loss therapies. The site aims to create 2,800 jobs and support local economies. Construction is set to begin in 2026, with operations expected by 2031, enhancing U.S. manufacturing capabilities. Read more

  • FDA Grants Fast Track Designation to Journavx: New Non-Opioid Pain Relief Option

    The FDA has approved Journavx (suzetrigine) 50 mg tablets, a pioneering non-opioid analgesic for moderate to severe acute pain in adults. This first-in-class medication targets sodium channels in the peripheral nervous system, offering pain relief without opioid addiction risks. Clinical trials show significant pain reduction and an acceptable safety profile. Read more

  • AstraZeneca’s Imfinzi Gains CHMP Support for Gastric Cancer

    The European Medicines Agency’s CHMP has positively evaluated AstraZeneca’s Imfinzi as a perioperative therapy for adult patients with resectable early-stage gastric and GEJ cancers. Based on MATTERHORN Phase III trial data, the regimen could significantly reduce recurrence and improve survival if approved by the European Commission. Read more

  • AstraZeneca Partners with CSPC to Innovate Obesity Treatments

    AstraZeneca has partnered with CSPC Pharmaceuticals to enhance its offerings for obesity and type 2 diabetes treatments. The collaboration grants AstraZeneca global rights outside China to novel therapies and CSPC’s drug discovery technology for four programmes, including a Phase I clinical trial asset. AstraZeneca will pay $1.2 billion upfront, with potential milestone payments. Read more

  • 700× Strategic Shift: AstraZeneca’s China Bet Questions Pharma’s Faith in India Post EU Deal

    AstraZeneca plans to invest $15 billion in China by 2030, significantly increasing its pharmaceutical capabilities and collaborations. This initiative follows a recent $20 million investment in India, raising questions about a strategic shift toward China for British pharmaceutical firms. Partnerships with local biotech companies are part of the effort to enhance drug innovation and manufacturing. Read more

  • FDA Approves Darzalex Faspro for Multiple Myeloma Treatment

    The FDA has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) combined with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed multiple myeloma ineligible for autologous stem cell transplant. Clinical trial results showed improved response rates and progression-free survival, though safety warnings were issued for potential adverse reactions. Read more

  • FDA Updates ZILBRYSQ Labeling for Patient Safety

    The FDA approved safety-related labeling changes for ZILBRYSQ (zilucoplan sodium) to enhance awareness of risks, particularly regarding severe meningococcal infections. Key updates include a pregnancy exposure registry and advice for vaccinations and antibiotic prophylaxis. Patients are urged to carry a Patient Safety Card and monitor for infection symptoms during treatment. Read more

  • GSK’s Arexvy Vaccine Approved for All Adults in EU

    GSK’s RSV vaccine, Arexvy, has received European Commission approval for use in all adults aged 18 and older, expanding its previous authorization which was limited to older and at-risk groups. This decision aims to protect adults from serious respiratory infections, addressing significant hospitalization rates associated with RSV. Read more

  • While Cruz Blamed Trump, India and the EU made history

    New Delhi / Brussels — As political fissures continued to widen in Washington, U.S. Senator Ted Cruz publicly blamed former President Donald Trump and senior White House aides for delays in key trade talks, India and the European Union finalized a landmark agreement that is being hailed as historic by leaders on both sides. In leaked audio shared with donors, Cruz accused Trump, Vice President JD Vance and other advisers of blocking progress on a potential India-U.S. trade deal, suggesting internal resistance in the U.S. administration was hindering negotiations.  Despite political turbulence in the United States, leaders in New… Read more